Atara Biotherapeutics (ATRA) announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company’s previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics Reports Strong Q1 2025 Results
- Atara Biotherapeutics Announces $16M Stock Offering
- Buy Rating for Atara Biotherapeutics: Strategic Focus and Financial Positioning Ahead of Key FDA Meeting
- Atara Biotherapeutics Appoints New Board Members Amid Restructuring
- Atara Biotherapeutics Announces Major Workforce Reduction